1. Home
  2. SNDX vs HLIT Comparison

SNDX vs HLIT Comparison

Compare SNDX & HLIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • HLIT
  • Stock Information
  • Founded
  • SNDX 2005
  • HLIT 1988
  • Country
  • SNDX United States
  • HLIT United States
  • Employees
  • SNDX N/A
  • HLIT N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • HLIT Radio And Television Broadcasting And Communications Equipment
  • Sector
  • SNDX Health Care
  • HLIT Technology
  • Exchange
  • SNDX Nasdaq
  • HLIT Nasdaq
  • Market Cap
  • SNDX 1.1B
  • HLIT 1.0B
  • IPO Year
  • SNDX 2016
  • HLIT 1995
  • Fundamental
  • Price
  • SNDX $15.71
  • HLIT $9.79
  • Analyst Decision
  • SNDX Strong Buy
  • HLIT Buy
  • Analyst Count
  • SNDX 10
  • HLIT 6
  • Target Price
  • SNDX $38.40
  • HLIT $11.50
  • AVG Volume (30 Days)
  • SNDX 2.2M
  • HLIT 1.0M
  • Earning Date
  • SNDX 11-04-2025
  • HLIT 10-27-2025
  • Dividend Yield
  • SNDX N/A
  • HLIT N/A
  • EPS Growth
  • SNDX N/A
  • HLIT 16.91
  • EPS
  • SNDX N/A
  • HLIT 0.58
  • Revenue
  • SNDX $77,933,000.00
  • HLIT $689,084,000.00
  • Revenue This Year
  • SNDX $585.73
  • HLIT N/A
  • Revenue Next Year
  • SNDX $94.17
  • HLIT $25.21
  • P/E Ratio
  • SNDX N/A
  • HLIT $17.00
  • Revenue Growth
  • SNDX 2126.66
  • HLIT 24.14
  • 52 Week Low
  • SNDX $8.58
  • HLIT $7.80
  • 52 Week High
  • SNDX $22.50
  • HLIT $15.46
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 58.19
  • HLIT 57.04
  • Support Level
  • SNDX $15.59
  • HLIT $9.78
  • Resistance Level
  • SNDX $16.65
  • HLIT $10.19
  • Average True Range (ATR)
  • SNDX 0.81
  • HLIT 0.26
  • MACD
  • SNDX -0.23
  • HLIT 0.03
  • Stochastic Oscillator
  • SNDX 28.68
  • HLIT 63.21

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About HLIT Harmonic Inc.

Harmonic Inc engaged in broadband access solutions that enable broadband operators to more efficiently and effectively deploy high-speed internet for data, voice, and video services for their customers and versatile and high-performance video delivery software, products, system solutions and services that enable its customers to efficiently create, prepare, store, playout and deliver a full range of high-quality broadcast and streaming video services to consumer devices, including televisions, personal computers, laptops, tablets, and smartphones. It has two segments, Broadband which provides broadband access solutions and related services, and Others; and Video business provides video processing and production and playout solutions and services, and Others.

Share on Social Networks: